Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 33 (31) 3635-3640
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
5
Parents:
810  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, CA33601, U10 CA031946, U10 CA033601, U10 CA180821, U10 CA180850, U10 CA180833, CA31946  
Corr. Author:
 
Authors:
                   
Networks:
CAPITAL, GREENVILLE, LAPS-MO011, LAPS-NY158, LAPS-OH007, NY018   
Study
CALGB-50401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Hema15, ORIGINAL REPORTS, Hematologic Malignancy